당뇨병 모니터링 기기 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Diabetes Monitoring Devices Market size is expected to reach USD 24.16 Billion in 2034 from USD 11.23 Billion (2025) growing at a CAGR of 8.89% during 2026-2034.

The global diabetes monitoring devices market is experiencing strong growth due to the rising global prevalence of diabetes. Factors such as sedentary lifestyles, unhealthy diets, and increasing obesity rates are contributing to a growing diabetic population. Diabetes monitoring devices help patients track blood glucose levels regularly, enabling better disease management and reducing the risk of complications associated with uncontrolled blood sugar levels.

Technological advancements are significantly transforming diabetes monitoring solutions. Continuous glucose monitoring (CGM) systems, wearable sensors, and smart glucose meters are gaining popularity because they provide real-time data and improved accuracy. Many modern devices also integrate with mobile applications, allowing patients and healthcare providers to monitor glucose trends and adjust treatment plans more effectively.

The future of the diabetes monitoring devices market appears promising as healthcare systems emphasize preventive care and digital health integration. Increasing adoption of wearable health technologies and remote patient monitoring is expected to support market growth. Expanding healthcare access in developing regions and ongoing innovations in non-invasive glucose monitoring technologies will further strengthen market opportunities.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Product Type

• Self-Monitoring Blood Glucose Devices
• Continuous Glucose Monitoring Devices

By Indication

• Type-I Diabetes
• Type-II Diabetes
• Gestational Diabetes

By End User

• Hospitals
• Clinics
• Ambulatory Surgical Center
• Home Care Settings
• other

COMPANIES PROFILED

• iSENS Inc, Ascensia Diabetes Care Holdings AG, Bayer AG, F HoffmannLa Roche Ltd, Johnson Johnson Services Inc, Medtronic plc, Dexcom Inc, Abbott Laboratories, Labiotech UG, ARKRAY Inc, Cnoga Medical Ltd, Sanofi SA, LifeScan Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL DIABETES MONITORING DEVICES MARKET: BY PRODUCT TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Product Type
• 4.2. Self-Monitoring Blood Glucose Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Continuous Glucose Monitoring Devices Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL DIABETES MONITORING DEVICES MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Type-I Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Type-II Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Gestational Diabetes Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL DIABETES MONITORING DEVICES MARKET: BY END USER 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast End User
• 6.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Ambulatory Surgical Center Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Home Care Settings Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. other Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL DIABETES MONITORING DEVICES MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Product Type
  • 7.2.2 By Indication
  • 7.2.3 By End User
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Product Type
  • 7.3.2 By Indication
  • 7.3.3 By End User
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Product Type
  • 7.4.2 By Indication
  • 7.4.3 By End User
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Product Type
  • 7.5.2 By Indication
  • 7.5.3 By End User
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Product Type
  • 7.6.2 By Indication
  • 7.6.3 By End User
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL DIABETES MONITORING DEVICES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 I-SENS Inc
  • 9.2.2 Ascensia Diabetes Care Holdings AG
  • 9.2.3 Bayer AG
  • 9.2.4 F. Hoffmann-La Roche Ltd
  • 9.2.5 Johnson & Johnson Services Inc
  • 9.2.6 Medtronic Plc
  • 9.2.7 Dexcom Inc
  • 9.2.8 Abbott Laboratories
  • 9.2.9 Labiotech UG
  • 9.2.10 ARKRAY Inc
  • 9.2.11 Cnoga Medical Ltd
  • 9.2.12 Sanofi S.A
  • 9.2.13 LifeScan Inc